Chardan lowered the firm’s price target on Metagenomi (MGX) to $11 from $12. The firm updated its model for Q2 financials and takes a slightly more conservative stance on programs/platform beyond hem A and the Ionis collaboration in light of the company’s increasing focus on pipeline execution and advancing gene editing platform competition. The firm noted its Q2 adjustments shift its price target lower.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MGX: